Cargando…

Exploring the best treatment options for BRAF-mutant metastatic colon cancer

The BRAF(V600E) mutation is a well-accepted poor prognostic factor in patients with metastatic colorectal cancer (mCRC), as it confers Ras-independent stimulation of the extracellular signal-regulated kinase/mitogen-activated protein kinase pathway involved in proliferation, migration, angiogenesis...

Descripción completa

Detalles Bibliográficos
Autores principales:	Taieb, Julien, Lapeyre-Prost, Alexandra, Laurent Puig, Pierre, Zaanan, Aziz
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2019
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6738120/ https://www.ncbi.nlm.nih.gov/pubmed/31353365 http://dx.doi.org/10.1038/s41416-019-0526-2

Ejemplares similares

Comment on: “Exploring the best treatment options for BRAF-mutant metastatic colon cancer”
por: Milano, Gérard, et al.
Publicado: (2020)

The Evolving Biomarker Landscape for Treatment Selection in Metastatic Colorectal Cancer
por: Taieb, Julien, et al.
Publicado: (2019)

Role of Circulating Tumor DNA in Gastrointestinal Cancers: Current Knowledge and Perspectives
por: Moati, Emilie, et al.
Publicado: (2021)

Emerging treatment options for BRAF-mutant colorectal cancer
por: Ursem, Carling, et al.
Publicado: (2018)

Next-Generation Sequencing Targeted Panel in Routine Care for Metastatic Colon Cancers
por: Bayle, Arnaud, et al.
Publicado: (2021)

Molecular targeted therapy of BRAF-mutant colorectal cancer
por: Ducreux, Michel, et al.
Publicado: (2019)

Comment on ‘KRAS-mutated plasma DNA as predictor of outcome from irinotecan monotherapy in metastatic colorectal cancer'
por: Tougeron, D, et al.
Publicado: (2014)

ERCC1, XRCC1 and GSTP1 Single Nucleotide Polymorphisms and Survival of Patients with Colon Cancer Receiving Oxaliplatin-Based Adjuvant Chemotherapy
por: Zaanan, Aziz, et al.
Publicado: (2014)

Dabrafenib and Trametinib in BRAF Mutant Metastatic Conjunctival Melanoma
por: Rossi, Ernesto, et al.
Publicado: (2019)

A Case Presentation of a Patient with Microsatellite Instability and BRAF Mutant Metastatic Colon Cancer and Bibliography Update
por: Thomopoulou, K., et al.
Publicado: (2019)

Current Therapeutic Strategies in BRAF-Mutant Metastatic Colorectal Cancer
por: Grassi, Elisa, et al.
Publicado: (2021)

Adult colonic intussusception: Surgery still the best option
por: Dungerwalla, M, et al.
Publicado: (2012)

Real‐world treatment and outcomes of patients with metastatic BRAF mutant colorectal cancer
por: Xu, Ting, et al.
Publicado: (2023)

Targeting HGF/c-Met Axis Decreases Circulating Regulatory T Cells Accumulation in Gastric Cancer Patients
por: Palle, Juliette, et al.
Publicado: (2021)

BRAF testing in metastatic colorectal carcinoma and novel, chemotherapy-free therapeutic options
por: Hummel, Michael, et al.
Publicado: (2021)

The Evolutionary Landscape of Treatment for BRAF(V600E) Mutant Metastatic Colorectal Cancer
por: Mauri, Gianluca, et al.
Publicado: (2021)

Treatment reality of patients with BRAF-mutant advanced/metastatic melanoma in Switzerland in the era of choice
por: Mangana, Joanna, et al.
Publicado: (2022)

Molecular mechanisms underlying the resistance of BRAF V600E-mutant metastatic colorectal cancer to EGFR/BRAF inhibitors
por: Xu, Ting, et al.
Publicado: (2022)

Optimizing the treatment of BRAF mutant melanoma
por: Settleman, Jeff
Publicado: (2014)

Dabrafenib for treatment of BRAF-mutant melanoma
por: Kainthla, Radhika, et al.
Publicado: (2013)

Bidirectional chemotherapy combining intraperitoneal docetaxel with intravenous 5-fluorouracil and oxaliplatin for patients with unresectable peritoneal metastasis from gastric cancer: the first study in Western countries
por: Lo Dico, Rea, et al.
Publicado: (2020)

Molecular Heterogeneity in BRAF-Mutant Gliomas: Diagnostic, Prognostic, and Therapeutic Implications
por: Lhermitte, Benoit, et al.
Publicado: (2023)

Plasma lncRNA expression profile as a prognostic tool in BRAF-mutant metastatic melanoma patients treated with BRAF inhibitor
por: Kolenda, Tomasz, et al.
Publicado: (2019)

BRAF-mutant hematopoietic malignancies
por: Abdel-Wahab, Omar, et al.
Publicado: (2014)

FOLFOX as second-line chemotherapy in patients with pretreated metastatic pancreatic cancer from the FIRGEM study
por: Zaanan, Aziz, et al.
Publicado: (2014)

Ampullary carcinoma prognostic markers
por: Perkins, Geraldine, et al.
Publicado: (2019)

BRAF Mutation Status in Circulating Tumor DNA from Patients with Metastatic Colorectal Cancer: Extended Mutation Analysis from the AGEO RASANC Study
por: Mas, Leo, et al.
Publicado: (2019)

Efficacy of BRAF and MEK Inhibition in Patients with BRAF-Mutant Advanced Melanoma and Germline CDKN2A Pathogenic Variants
por: Spagnolo, Francesco, et al.
Publicado: (2021)

Current Advances in the Treatment of BRAF-Mutant Melanoma
por: Patel, Hima, et al.
Publicado: (2020)

Efficacy and safety of anti-PD1 monotherapy or in combination with ipilimumab after BRAF/MEK inhibitors in patients with BRAF mutant metastatic melanoma
por: Pires da Silva, Ines, et al.
Publicado: (2022)

First-Line Treatment in EGFR Mutant Non-Small Cell Lung Cancer: Is There a Best Option?
por: Bulbul, Ajaz, et al.
Publicado: (2018)

BET and BRAF inhibitors act synergistically against BRAF‐mutant melanoma
por: Paoluzzi, Luca, et al.
Publicado: (2016)

Medical debulking with BRAF/MEK inhibitors in aggressive BRAF-mutant craniopharyngioma
por: Di Stefano, Anna Luisa, et al.
Publicado: (2020)

Targeting mutant BRAF in colorectal cancer
por: Carroll, David, et al.
Publicado: (2013)

Corticosteroid-Refractory Myositis After Dual BRAF and MEK Inhibition in a Patient with BRAF V600E-Mutant Metastatic Intrahepatic Cholangiocarcinoma
por: DiPeri, Timothy P., et al.
Publicado: (2022)

BRAF L485–P490 deletion mutant metastatic melanoma sensitive to BRAF and MEK inhibition: A case report and literature review
por: Zhang, Simeng, et al.
Publicado: (2023)

BRAF p.Val600Glu (V600E) Testing for Assessment of Treatment Options in Metastatic Colorectal Cancer
por: Lea, Andrew, et al.
Publicado: (2010)

Encorafenib/binimetinib for the treatment of BRAF-mutant advanced, unresectable, or metastatic melanoma: design, development, and potential place in therapy
por: Sun, James, et al.
Publicado: (2018)

Endosomal acidification inhibitors for the treatment of BRAF mutant tumors
por: Espinosa, Lluís
Publicado: (2015)

Resistance surveillance in a BRAF mutant melanoma patient on long-term BRAF-inhibitor treatment
por: Mak, Gabriel, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_pmv3peqodi1egsf8776l2gt1af